Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cell Therapeutics Inc Announces Market Access Granted In Italy For Aggressive Non-Hodgkin Lymphoma Treatment, PIXUVRI (pixantrone)


Monday, 8 Jul 2013 02:28am EDT 

Cell Therapeutics Inc announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). Pixantrone has been classified by AIFA for use in hospitals and additional details on the pricing and reimbursement conditions for PIXUVRI in Italy will be provided coincident with the publication of the "Determina" of AIFA in the Official Gazette, which is expected to take 6 to 8 weeks. 

Company Quote

2.44
0.05 +2.09%
4:00pm EDT